1. Scrip
  2. >>Advanced Therapies
  3. >>Cell Therapies

Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT

 
• By Joseph Haas

Lyell believes ImmPACT’s dual CD19/20-targeted CAR-T could offer better response rates than Yescarta or Breyanzi and will focus on IMPT-314 while terminating much of its own pipeline.

(Shutterstock)

Despite significant fundraising results to date, Lyell Immunopharma has been stuck in neutral with its own cancer cell therapy efforts, and the firm revealed on 24 October that it is merging with privately held ImmPACT Bio, bringing that company’s Phase I chimeric antigen receptor T-cell (CAR-T) therapy candidate into its pipeline and shuttering some of its own existing R&D candidates. Among other changes, Lyell is ceasing its efforts in tumor-infiltrating lymphocyte (TIL) therapies.

Key Takeaways
  • Lyell will pay $30m up front plus a sizeable equity stake to acquire ImmPACT Bio and its Phase I dual anti-CD19/20 CAR-T therapy for B-cell non-Hodgkin lymphoma.

On a same-day investor call, Lyell CEO Lynn Sealy said ImmPACT’s lead candidate, the dual-targeting CD19/20-directed CAR-T candidate IMPT-314, may...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell Therapies

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition

 
• By Alaric DeArment

The drugmaker will spend up to $2.1bn to acquire the privately held biotech firm and its targeted lipid nanoparticle technology platform, with an anti-CD19 asset in the clinic.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.